Taiwan Liposome Co (TLC, 台灣微脂體) is seeking streamlined US regulatory approval for its efforts in treating pediatric rhabdomyosarcoma, a rare disorder affecting about 350 children in Taiwan.
TLC, which developed a proprietary lipid-assembled delivery platform for nanomedicine injections, is looking to qualify for the US Food and Drug Administration’s (FDA) Rare Pediatric Disease Priority Review Voucher program that provides incentives for sponsors that receive approval for biologics license applications.
The company’s technology traps the active pharmaceutical ingredient in multiple layers of lipids to promote fast-acting and sustained release of active pharmaceutical ingredients, as well as reducing the frequency of required injections.
The company’s treatments can also be administered with smaller-gauge needles, which provides broader use for physicians.
The voucher grants priority review of a subsequent marketing application for a different product and the treatment can be sold for more than US$100 million to other drug developers vying to beat rivals to the market, TLC president George Yeh (葉志鴻) said at an earnings conference in Taipei.
To earn the voucher, the company would start clinical trials for TLC178, its target-delivered nanomedicine for managing tumor growth, before the end of the first half of the year, Yeh said, adding that studies for rare diseases are single-armed.
In addition to TLC178, three other products are expected to enter the trial stage before the end of next year, Yeh said, adding that the firm’s lipid-based technology has produced favorable results in clinical trials.
TLC599, a sustained release therapy for the treatment of osteoarthritis pain, has shown minimal cartilage damage among patients while providing fast-acting as well as sustained pain relief, Yeh said.
TLC590, which brings sustained release delivery technology to the common local anesthetic ropivacaine, is designed as an alternative post-surgery pain management therapy to combat rising opioid addiction, he said.
Similarly, TLC399 provides sustained release for macular edema without the need to insert an implant in the eye, he added.
Overall, the US FDA has been very positive about alternatives for opioids in previous meetings with the company, Yeh said.
TLC’s pain management products are expected to be highly competitive in the US market as they can be produced in low-cost manufacturing environments, he said.
Regarding the company’s plans to list American depositary receipts (ADRs) on the NASDAQ, Yeh said that the move would help raise the company’s profile in the US, its biggest target market.
The issue price is expected to be more than NT$72 per ADR, the same level the company’s shares were trading at the time of application in November last year.
The company decided on an overseas listing because it is tougher to gain a higher valuation in Taiwan with its investment requirements, he added.
The company, which is still seeking market approval for its new drugs, posted net losses of NT$873 million (US$29.79 million) for last year.
Shares of TLC yesterday dipped 6.61 percent to NT$100.5 in Taipei trading.
Stephen Garrett, a 27-year-old graduate student, always thought he would study in China, but first the country’s restrictive COVID-19 policies made it nearly impossible and now he has other concerns. The cost is one deterrent, but Garrett is more worried about restrictions on academic freedom and the personal risk of being stranded in China. He is not alone. Only about 700 American students are studying at Chinese universities, down from a peak of nearly 25,000 a decade ago, while there are nearly 300,000 Chinese students at US schools. Some young Americans are discouraged from investing their time in China by what they see
MAJOR DROP: CEO Tim Cook, who is visiting Hanoi, pledged the firm was committed to Vietnam after its smartphone shipments declined 9.6% annually in the first quarter Apple Inc yesterday said it would increase spending on suppliers in Vietnam, a key production hub, as CEO Tim Cook arrived in the country for a two-day visit. The iPhone maker announced the news in a statement on its Web site, but gave no details of how much it would spend or where the money would go. Cook is expected to meet programmers, content creators and students during his visit, online newspaper VnExpress reported. The visit comes as US President Joe Biden’s administration seeks to ramp up Vietnam’s role in the global tech supply chain to reduce the US’ dependence on China. Images on
New apartments in Taiwan’s major cities are getting smaller, while old apartments are increasingly occupied by older people, many of whom live alone, government data showed. The phenomenon has to do with sharpening unaffordable property prices and an aging population, property brokers said. Apartments with one bedroom that are two years old or older have gained a noticeable presence in the nation’s six special municipalities as well as Hsinchu county and city in the past five years, Evertrust Rehouse Co (永慶房產集團) found, citing data from the government’s real-price transaction platform. In Taipei, apartments with one bedroom accounted for 19 percent of deals last
US CONSCULTANT: The US Department of Commerce’s Ursula Burns is a rarely seen US government consultant to be put forward to sit on the board, nominated as an independent director Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest contract chipmaker, yesterday nominated 10 candidates for its new board of directors, including Ursula Burns from the US Department of Commerce. It is rare that TSMC has nominated a US government consultant to sit on its board. Burns was nominated as one of seven independent directors. She is vice chair of the department’s Advisory Council on Supply Chain Competitiveness. Burns is to stand for election at TSMC’s annual shareholders’ meeting on June 4 along with the rest of the candidates. TSMC chairman Mark Liu (劉德音) was not on the list after in December last